Eye

Blepharitis - Pipeline Insight, 2021

Fri, 19 Mar 2021 14:59:26 +0000

DelveInsight’s, “Blepharitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blepharitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Blepharitis Understanding Blepharitis: Overview Blepharitis is a common eye condition that makes your eyelids red, swollen, irritated, and itchy. It can cause crusty dandruff-like flakes on your eyelashes. Blepharitis can be uncomfortable. But it isn’t contagious, and it usually doesn’t cause any lasting damage to your eyes. The main treatment for blepharitis is regularly cleaning your eyelids and keeping them free of crusts. Blepharitis usually doesn’t go away completely, but you can take steps to manage your symptoms. Talk to your eye doctor about what’s causing your blepharitis and the b...

$1,500.00

Acute optic neuritis - Pipeline Insight, 2021

Fri, 19 Mar 2021 14:59:26 +0000

DelveInsight’s, “Acute optic neuritis - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Acute optic neuritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Acute optic neuritis Understanding Acute optic neuritis: Overview Optic neuritis is an inflammatory disease of the optic nerve and is frequently the presenting sign of multiple sclerosis. These patients commonly experience pain on eye movement and then suddenly have a major loss in visual acuity, usually in one eye. The blindness often resolves in 6-8 weeks. Six months after the episode of blindness, more than half of the patients have some visual changes, including deficits in color vision, contrast sensitivity, and light brightness. The current treatment is steroids, which reduce...

$1,500.00

Keratoconus- Market Insight, Epidemiology and Market Forecast -2030

Wed, 14 Oct 2020 15:56:15 +0000

DelveInsight’s ‘Keratoconus (KC) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Keratoconus (KC), historical and forecasted epidemiology as well as the Keratoconus (KC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Keratoconus (KC) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Keratoconus (KC) market size from 2017 to 2030. The report also covers current Keratoconus (KC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2017–2030 Keratoconus (KC) Disease Understanding and Treatment Algorithm Keratoconus (KC) Overview Keratoconus (KC) also known as the conical cornea, is an eye (ocular) disorder ch...

$6,950.00

Glaucoma - Pipeline Review, H1 2020

Thu, 07 May 2020 13:39:47 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H1 2020, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug targe...

$2,000.00

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2020

Thu, 07 May 2020 13:39:47 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H1 2020, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development,...

$2,000.00

Cataract - Pipeline Review, H1 2020

Thu, 07 May 2020 13:13:49 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H1 2020, provides an overview of the Cataract (Ophthalmology) pipeline landscape.

Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its c...

$2,000.00

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:13:09 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H2 2019, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development,...

$2,000.00

Eye Infections Market Insights, Epidemiology and Market Forecast- 2028

Wed, 13 Nov 2019 11:03:24 +0000

DelveInsight's “Eye Infections - Market Insights, Epidemiology and Market Forecast – 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028. Markets Covered • United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2017-2028 Eye Infections Understanding and Treatment Algorithm The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Eye Infections in the US, Europe, and Japan are also provided in the report. Eye Infections Epidemiology This section provide the insights about historical and ...

$6,250.00

Eye Neoplasms Market Insights, Epidemiology and Market Forecast- 2028

Wed, 13 Nov 2019 11:03:24 +0000

DelveInsight's “Eye Neoplasms - Market Insights, Epidemiology and Market Forecast – 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028. Markets Covered • United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2017-2028 Eye Neoplasms Understanding and Treatment Algorithm The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Eye Neoplasms in the US, Europe, and Japan are also provided in the report. Eye Neoplasms Epidemiology This section provide the insights about historical and curr...

$6,250.00

Global Optometry/ Eye Examination Equipment Market Research Report 2018

Thu, 06 Dec 2018 14:49:37 +0000

Optometry/ Eye Examination Equipment Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). The report firstly introduced the Optometry/ Eye Examination Equipment basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. The report includes six parts, dealing with: 1.) Basic Information; 2.) Asia Optometry/ Eye Examination Equipment Market; 3.) North American Optometry/ Eye Examination Equipment...

$2,850.00

Cataract - Pipeline Review, H2 2018

Thu, 29 Nov 2018 13:32:16 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H2 2018, provides an overview of the Cataract (Ophthalmology) pipeline landscape.

Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its c...

$2,000.00

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2018

Tue, 10 Apr 2018 12:37:44 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2018, provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) pipeline landscape.

Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties, rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics und...

$2,000.00

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2026

Wed, 11 Apr 2018 15:14:21 +0000

Summary

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 30-50%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease.

Most drugs prescribed for glaucoma can be placed into one of four drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonis...

$10,995.00

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018

Tue, 10 Apr 2018 12:51:56 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under developmen...

$2,000.00

Bacterial Conjunctivitis - Pipeline Review, H1 2018

Tue, 10 Apr 2018 12:37:44 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecul...

$2,000.00

Uveitis - Pipeline Review, H1 2018

Tue, 10 Apr 2018 12:51:56 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H1 2018, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by sta...

$2,000.00

Open-Angle Glaucoma Global Clinical Trials Review, H2, 2016

Wed, 11 Jan 2017 12:42:31 +0000

Summary

GlobalData's clinical trial report, “Open-Angle Glaucoma Global Clinical Trials Review, H2, 2016" provides an overview of Open-Angle Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Open-Angle Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain...

$2,500.00

Cataract Global Clinical Trials Review, H2, 2016

Wed, 11 Jan 2017 12:42:31 +0000

Summary

GlobalData's clinical trial report, “Cataract Global Clinical Trials Review, H2, 2016" provides an overview of Cataract clinical trials scenario. This report provides top line data relating to the clinical trials on Cataract. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*N...

$2,500.00

Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H2, 2016

Wed, 11 Jan 2017 12:42:31 +0000

Summary

GlobalData's clinical trial report, “Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H2, 2016" provides an overview of Keratoconjunctivitis sicca (Dry Eye) clinical trials scenario. This report provides top line data relating to the clinical trials on Keratoconjunctivitis sicca (Dry Eye). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and help...

$2,500.00

Epiomic Epidemiology Series: Dry Eye Syndrome Forecast in 14 Major Markets 2016-2026

Thu, 06 Oct 2016 11:26:22 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Dry Eye Syndrome in 14 Major Markets Dry Eye Syndrome (DES), also known as Keratoconjunctivitis sicca, is a multi-factorial disorder of the tear film which occurs due to a tear deficiency or excessive tear evaporation. Dry Eye Syndrome is categorized by inflammation of the ocular surface and the lachrymal glands. Patients will often report ocular discomfort as well as the inclusion of a variety of symptoms such as excessive tearing and blurred vision. This report provides the current prevalent population for Dry Eye Syndrome across 14 Major Markets (USA, France, Germany, Italy, Spain, UK, Japan, China, India, Brazil, Mexico, Australia, Canada and S.Korea) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Dr...

$6,400.00

Dry eye disease- Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Dry eye disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Dry eye disease forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Dry eye disease till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Dry eye disease market. • Identifying patient populations in the global “Dry eye diseasemarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Dry eye disease therapeutics in each of the markets covered. • To understand t...

$4,950.00

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

Fri, 17 Jun 2016 09:15:01 +0000

Summary

Global Markets Direct’s, ‘Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016’, provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/univer...

$2,000.00

Retinal Vein Occlusion - Pipeline Review, H1 2016

Tue, 07 Jun 2016 19:33:56 +0000

Summary

Global Markets Direct’s, ‘Retinal Vein Occlusion - Pipeline Review, H1 2016’, provides an overview of the Retinal Vein Occlusion pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conference...

$2,000.00

Macular Edema - Pipeline Review, H1 2016

Tue, 07 Jun 2016 19:33:56 +0000

Summary

Global Markets Direct’s, ‘Macular Edema - Pipeline Review, H1 2016’, provides an overview of the Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentatio...

$2,000.00

Open-Angle Glaucoma - Pipeline Review, H1 2016

Thu, 02 Jun 2016 09:19:17 +0000

Summary

Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H1 2016’, provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filin...

$2,000.00